New cocktail aims to turn inoperable stomach cancer into a surgical success

NCT ID NCT07194005

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times

Summary

This study tests a combination of three drugs (RC48, sintilimab, and SOX chemotherapy) in 30 people with advanced stomach cancer that cannot be removed by surgery. The goal is to shrink the tumor enough so that surgery becomes possible. Participants receive 4 to 6 cycles of treatment, and if the cancer shrinks enough, they undergo surgery to remove it. The main measure of success is whether the cancer can be completely removed with no leftover cells under the microscope.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200230, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GASTRIC CANCER